Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ipsen S.A.
(OP:
IPSEF
)
N/A
UNCHANGED
Last Price
Updated: 11:28 AM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
132.50
Today's Range
N/A - N/A
52wk Range
108.75 - 117.60
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
August 21, 2023
Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs
Via
Benzinga
What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur
May 22, 2023
On Friday, FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's ICPT Ocaliva 25 mg, also known as Obeticholic acid...
Via
Benzinga
Performance
More News
Read More
France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline
January 09, 2023
Via
Benzinga
Why Merrimack Shares Are Surging Over 200% Today?
November 09, 2022
Via
Benzinga
Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure
August 03, 2022
Via
Benzinga
Why Is Epizyme (EPZM) Stock Up 75% Today?
June 27, 2022
Via
InvestorPlace
Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why
June 27, 2022
Via
Benzinga
Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer
May 03, 2022
Via
Benzinga
EMA's Scientific Committee Backs Expanded Use Of Exelixis, Ipsen's Cabometyx In Thyroid Cancer
March 25, 2022
Via
Benzinga
Ipsen's Sohonos Scores Canadian Approval For Rare Connective Tissue Disease
January 24, 2022
Via
Benzinga
Genfit Shares Rally After Ipsen Buys Rights To Its Late-Stage Kidney Disease Treatment Hopeful
December 17, 2021
Via
Benzinga
Ipsen Stock Declines After Pulling Rare Disease Application
August 13, 2021
Via
Benzinga
Exposures
Product Safety
Exicure Stock Surges On Over $1B Option Licensing Pact With Ipsen For Rare Neurodegenerative Disorders
August 02, 2021
Via
Benzinga
Ipsen Beefs Up Pre-Clinical Oncology Pipeline With Over $850M Deal With BAKX Therapeutics
July 27, 2021
Via
Benzinga
Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer
June 28, 2021
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.